Chronic Leukemias

A collection of features and news articles published in ASH Clinical News related to chronic leukemias.

On location

Can Women With CML Safely Continue TKIs During Pregnancy?

Most women with chronic myeloid leukemia (CML) who received treatment with tyrosine kinase inhibitors (TKIs) and became pregnant had a normal childbirth, with no...
On location

Single-Agent Acalabrutinib Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia

According to results from the phase III ASCEND trial, treatment with acalabrutinib as a single agent improved progression-free survival (PFS) compared with idelalisib or...

Robert Kreitman: Delayed Versus Concurrent Rituximab in Hairy Cell Leukemia

Robert Kreitman, MD, shares results from a new study suggesting patients with hairy cell leukemia should receive rituximab concurrently with frontline cladribine.
On location

Flumatinib Superior to Imatinib in Chronic-Phase Chronic Myeloid Leukemia

Flumatinib, a second-generation tyrosine kinase inhibitor (TKI), led to more molecular responses that were also deeper, compared with imatinib, in patients with newly diagnosed...
On location

Should Patients With Hairy Cell Leukemia Receive Delayed or Concurrent Rituximab?

For more than 30 years, the standard firstline treatment of hairy cell leukemia (HCL) has been single-agent purine analog therapy, usually cladribine, but a...

Hematologic Malignancies Drive In-Hospital Death Rates

In the past 17 years, the overall rate of in-hospital deaths among patients with hematologic malignancies has decreased by 30 percent, with a corresponding...

Venetoclax Approved for CLL and SLL

The U.S. Food and Drug Administration (FDA) approved venetoclax (plus obinutuzumab) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small...
You Make the Call

Is there a genetic risk for familial CLL?

This month, Kanti R. Rai, MD, discusses familial chronic lymphocytic leukemia. And don't forget to check out next month's clinical dilemma - send in your...
WIB_icon

Venetoclax Plus Obinutuzumab Confers High MRD-Negative Rates in CLL

Results from a phase Ib study demonstrated that the combination of the BCL2 inhibitor venetoclax with the anti-CD20 monoclonal antibody obinutuzumab was safe and...

The Year in FDA Approvals

In the past year, the U.S. Food and Drug Administration (FDA) approved several therapies for the treatment of myeloid malignancies, including the first treatment...

SHARE